Key result
Two novel NR3C2 mutations (Y134X and 2125delA) lacking aldosterone binding and transactivation abilities were identified in Italian patients with renal PHA1.
Case-Control (n=93)
Novel NR3C2 mutations (Y134X and 2125delA) cause loss of mineralocorticoid receptor function in renal PHA1, and the c.722T SNP is highly prevalent in the Italian population.
Supports NR3C2 sequencing in suspected renal PHA1; extends loss-of-function variant spectrum but remains hypothesis-generating.
OBJECTIVE: The renal form of pseudohypoaldosteronism type 1 (PHA1) is a rare disease caused by mutations in the human mineralocorticoid receptor gene (NR3C2). DESIGN: Aim of the study was to analyze the NR3C2 gene in three Italian patients with clinical signs of renal PHA1 and to evaluate the distribution of the -2G > C, c.538A > G, and c.722C > T single nucleotide polymorphism (SNP) pattern in the PHA1 patients and in 90 controls of the same ethnic origin. METHODS: Analysis of the NR3C2 gene sequence and of the polymorphic SNP markers. Functional characterization of the detected novel NR3C2 mutations utilizing aldosterone-binding assays and reporter gene transactivation assays. RESULTS: One novel nonsense (Y134X) and one novel frameshift (2125delA) mutation were detected. They exhibited no aldosterone binding and no transactivation abilities. No mutation was detected in the third patient. Haploinsufficiency of NR3C2 was ruled out by microsatellite analysis in this patient. The c.722T SNP was detected in 97% of alleles in the Italian population which is significantly different from the general German or US population. CONCLUSIONS: Molecular analysis of the NR3C2 gene in PHA1 patients is warranted to detect novel mutations in order to clarify the underlying genetic cause, which may extend the insight into relevant functional regions of the hMR protein. The effect the different distribution of the c.722T SNP is not clear to date. Further studies are necessary to provide evidence as to a possible advantage of a less sensitive hMR in southern countries.
No takes yet. Share an insight, caveat, or question.
Balsamo et al. (2007) conducted a case-control in pseudohypoaldosteronism type 1 (PHA1) (n=93). NR3C2 gene mutations vs. Controls was evaluated on Detection of NR3C2 gene mutations and SNP distribution. Two novel NR3C2 mutations (Y134X and 2125delA) lacking aldosterone binding and transactivation abilities were identified in Italian patients with renal PHA1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: